MARKET

CCXI

CCXI

ChemoCentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.98
-0.10
-0.59%
Opening 14:03 09/22 EDT
OPEN
17.08
PREV CLOSE
17.08
HIGH
17.28
LOW
16.76
VOLUME
858.43K
TURNOVER
--
52 WEEK HIGH
70.29
52 WEEK LOW
9.53
MARKET CAP
1.19B
P/E (TTM)
-9.5976
1D
5D
1M
3M
1Y
5Y
Here’s Why ChemoCentryx (CCXI) Landed in Wasatch Small Cap’s Detractor List
Wasatch Global Investors, an investment management firm, published its “Wasatch Small Cap Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 6.32% was recorded by the fund’s investor class for the Q2 of 2...
Insider Monkey · 1d ago
Should You Be Tempted To ‘Sell’ ChemoCentryx (CCXI) Stock?
Wasatch Micro Cap Fund recently released its Q2 2021 Investor Letter, a copy of which you can download here. The fund posted a return of 3.11% for the quarter, underperforming its benchmark, the Russell Microcap Index which returned 4.14% in the same quart...
Insider Monkey · 2d ago
Is the Options Market Predicting a Spike in ChemoCentryx (CCXI) Stock?
Zacks.com · 09/15 13:47
ChemoCentryx's Return On Capital Employed Overview
Benzinga Pro data, ChemoCentryx (NASDAQ:CCXI) reported Q2 sales of $1.81 million. Earnings fell to a loss of $38.74 million, resulting in a 32.09% decrease from last quarter.
Benzinga · 09/13 16:57
Catalyst watch for next week: Apple, Zoom Video, Palo Alto Networks in the spotlight; OPEC update
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 09/10 19:00
ChemoCentryx (CCXI) Up 10.5% Since Last Earnings Report: Can It Continue?
Zacks.com · 09/08 09:15
ChemoCentryx to Participate in Two Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: 2021 Virtual Wells Fargo ...
GlobeNewswire · 09/02 12:30
Tang Capital Management Llc Buys Heron Therapeutics Inc, Vincerx Pharma Inc, Altimmune Inc, ...
GuruFocus News · 08/24 18:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CCXI. Analyze the recent business situations of ChemoCentryx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CCXI stock price target is 32.50 with a high estimate of 64.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 211
Institutional Holdings: 46.52M
% Owned: 66.54%
Shares Outstanding: 69.90M
TypeInstitutionsShares
Increased
55
6.65M
New
33
3.77M
Decreased
38
3.15M
Sold Out
69
17.87M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.14%
Pharmaceuticals & Medical Research
-0.07%
Key Executives
Chairman/Chief Executive Officer/President/Director
Thomas Schall
Chief Financial Officer/Executive Vice President/Chief Administrative Officer/Secretary/Director/IR Contact Officer
Susan Kanaya
Chief Operating Officer/Executive Vice President
Tausif Butt
Treasurer
Markus Cappel
Lead Director/Independent Director
Thomas Edwards
Independent Director
Joseph Feczko
Independent Director
Rita Jain
Independent Director
Henry McKinnell
Independent Director
Geoffrey Parker
Independent Director
James Tyree
No Data
About CCXI
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Webull offers kinds of ChemoCentryx Inc stock information, including NASDAQ:CCXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CCXI stock methods without spending real money on the virtual paper trading platform.